• DiscoveryProbe Bioactive Compound Library Plus in Mechanisti

  2026-07-08

  Explore how the DiscoveryProbe Bioactive Compound Library Plus empowers advanced mechanistic ligand screening, optimizing assay precision and translational research. This article reveals unique strategies for integrating protease inhibitors and pathway analysis, grounded in recent biophysical advances.

• Ceapin-A7: Selective ER Stress Blocker for ATF6α Pathway Inh

  2026-07-07

  Ceapin-A7 is a selective ER stress blocker that specifically inhibits ATF6α pathway activation, providing a precise tool for unfolded protein response research. Its benchmark IC50 of 0.59 μM and high selectivity make it a reference compound in endoplasmic reticulum stress signaling studies. APExBIO supplies Ceapin-A7 as a validated resource for biochemical and cell biology workflows.

• AMPK’s Role in Autophagy: New Mechanistic Insights and Impli

  2026-07-07

  A recent study overturns the prevailing model of AMPK as a universal activator of autophagy under energy stress, revealing it instead inhibits ULK1 and suppresses autophagy initiation. These findings reshape experimental strategies for dissecting autophagy and energy stress pathways, with direct relevance to disease models and selective pathway inhibition.

• HBTU in Peptide Synthesis: Precision, Workflow, and Troubles

  2026-07-06

  HBTU’s mild activation and resistance to racemization make it indispensable for synthesizing sophisticated, cancer-selective peptides. Explore how APExBIO’s HBTU empowers researchers to streamline experimental workflows, minimize side reactions, and address common synthesis challenges in next-generation peptide therapeutics.

• Advanced In Vitro Assays for Evaluating Cancer Drug Response

  2026-07-06

  Schwartz’s dissertation introduces a refined approach for distinguishing between growth inhibition and cell death in anti-cancer drug testing, highlighting the limitations of traditional viability metrics. These findings offer a more nuanced understanding of drug action in vitro, with significant implications for the evaluation of DNA topoisomerase II inhibitors and other targeted agents.

• Cy3 NHS Ester (Non-Sulfonated): Technical Guide for Protein

  2026-07-05

  Cy3 NHS ester (non-sulfonated) enables efficient, specific covalent labeling of amino groups in proteins, peptides, and oligonucleotides for high-sensitivity fluorescence detection. It is suited for workflows requiring organic co-solvents, but not for applications needing water-only labeling or long-term solution storage. For delicate proteins sensitive to organic solvents, consider sulfonated analogs instead.

• Thymoquinone in Cardiotoxicity Research: Workflows & Trouble

  2026-07-04

  Thymoquinone, a potent 2-isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione, is redefining cardioprotective research through its dual antioxidant and anti-ferroptotic properties. This article delivers actionable protocols, workflow enhancements, and troubleshooting insights, translating the latest mechanistic findings into bench-ready guidance for maximizing APExBIO’s Thymoquinone as a research probe.

• Enhancing Kidney-Targeted mRNA Nanoparticle Loading via Exci

  2026-07-03

  This study explores the use of various excipients to boost the mRNA loading capacity and stability of polymeric mesoscale nanoparticles specifically designed for kidney targeting. By characterizing excipient-mRNA interactions, the research offers practical strategies to improve delivery efficiency and functional protein expression in renal applications.

• Adefovir (GS-0393): Mechanistic Precision for Translational

  2026-07-03

  This article provides translational researchers with a strategic, mechanistically detailed exploration of Adefovir (GS-0393) as a benchmark tool for hepatitis B virus (HBV) research and renal transporter studies. We examine its biochemical rationale, experimental validation, and clinical relevance, offering protocol guidance and a nuanced outlook on its role in advancing antiviral research. Drawing on peer-reviewed data, product intelligence, and recent cross-domain findings, we differentiate APExBIO’s offering and position Adefovir as a linchpin for workflow innovation.

• SIRT1/2 Inhibitor IV (Cambinol): Precision Tools for Non-His

  2026-07-02

  Explore how SIRT1/2 Inhibitor IV (cambinol) enables advanced investigation of SIRT1/2-regulated non-histone lactylation and astrocyte polarization. This article offers unique protocol insights and applications in CNS injury models, providing researchers with actionable guidance beyond current literature.

• Advances in Antiemetic Therapy: Palonosetron in CINV Managem

  2026-07-02

  The reviewed study systematically analyzes palonosetron hydrochloride's mechanism, efficacy, and clinical positioning for chemotherapy- and radiotherapy-induced nausea and vomiting (CINV). Its higher receptor affinity and extended half-life underpin superior efficacy, particularly for delayed CINV, informing updated clinical guidelines and setting a benchmark for antiemetic research and protocol design.

• FLT3-TAZ Signaling Drives Drug Resistance in Blast Phase CML

  2026-07-01

  Shin et al. reveal that FLT3 expression activates a JAK-STAT3-TAZ-TEAD-CD36 pathway driving drug resistance in blast phase chronic myeloid leukemia (BP-CML), independent of BCR::ABL1 mutations. Their study demonstrates that targeting FLT3, alone or in combination with BCR::ABL1 inhibitors, overcomes resistance and offers a new therapeutic strategy for FLT3-positive BP-CML.

• Sequencing Therapies in Waldenström Macroglobulinemia: CXCR4

  2026-07-01

  This article reviews the recent literature on therapeutic sequencing in Waldenström macroglobulinemia, emphasizing the impact of MYD88 and CXCR4 mutations on treatment selection and outcomes. It highlights how emerging CXCR4 antagonists and precision genomics are informing clinical decision-making and translational research.

• Gingerenone A Restores Sunitinib Sensitivity by Targeting LD

  2026-06-30

  This study identifies gingerenone A as a metabolic inhibitor that suppresses LDHA-driven glycolysis, disrupts HIF-1α signaling, and overcomes sunitinib resistance in renal cell carcinoma. The findings highlight a promising strategy for enhancing TKI efficacy through targeted metabolic intervention.

• Sequential Immunotherapy via MMP-2 Responsive Liposomes in B

  2026-06-30

  This study introduces a dual-targeting, MMP-2 responsive liposomal system for sequential delivery of a PD-1/PD-L1 blockade peptide and an IDO inhibitor, aiming to remodel the immunosuppressive microenvironment in breast cancer. The approach demonstrates enhanced specificity and efficacy compared to traditional immunotherapy, providing a promising direction for nanomedicine-driven cancer treatment.

451 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page